Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase deficiency in patients with colorectal cancer: A single-institution experience by Murphy, Con et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Cost implications of reactive versus prospective testing for
dihydropyrimidine dehydrogenase deficiency in patients with colorectal
cancer: A single-institution experience
Author(s) Murphy, Con; Byrne, Stephen; Ahmed, Gul; Kenny, Andrew; Gallagher,
James; Harvey, Harry; O'Farrell, Eoin; Bird, Brian
Publication date 2018-10-01
Original citation Murphy, C., Byrne, S., Ahmed, G., Kenny, A., Gallagher, J., Harvey, H.,
O’Farrell, E. and Bird, B., 2018. Cost implications of reactive versus
prospective testing for dihydropyrimidine dehydrogenase deficiency in
patients with colorectal cancer: a single-institution experience. Dose-
Response, 16(4), (1559325818803042).
DOI:10.1177/1559325818803042





Access to the full text of the published version may require a
subscription.







Cost Implications of Reactive
Versus Prospective Testing for
Dihydropyrimidine Dehydrogenase
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Abstract
Background: Severe toxicity is experienced by a substantial minority of patients receiving fluoropyrimidine-based che-
motherapy, with approximately 20% of these severe toxicities attributable to polymorphisms in the DPYD gene. The DPYD codes
for the enzyme dihydropyrimidine dehydrogenase (DPD) important in the metabolism of fluoropyrimidine-based chemotherapy.
We questioned whether prospective DPYD mutation analysis in all patients commencing such therapy would prove more cost-
effective than reactive testing of patients experiencing severe toxicity.
Methods: All patients experiencing severe toxicity from fluoropyrimidine-based chemotherapy for colorectal cancer in an Irish
private hospital over a 3-year period were tested for 4 DPYD polymorphisms previously associated with toxicity. The costs
associated with an index admission for toxicity in DPD-deficient patients were examined. A cost analysis was undertaken
comparing the anticipated cost of implementing screening for DPYD mutations versus current usual care. One-way sensitivity
analysis was conducted on known input variables. An alternative scenario analysis from the perspective of the Irish health-care
payer (responsible for public hospitals) was also performed.
Results: Of 134 patients commencing first-line fluoropyrimidine chemotherapy over 3 years, 30 (23%) patients developed grade
3/4 toxicity. Of these, 17% revealed heterozygote DPYD mutations. The cost of hospitalization for the DPYD-mutated patients was
€232 061, while prospectively testing all 134 patients would have cost €23 718. Prospective testing would result in cost savings
across all scenarios.
Conclusions: The cost of hospital admission for severe chemotherapy-related toxicity is significantly higher than the cost of
prospective DPYD testing of each patient commencing fluoropyrimidine chemotherapy.
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Introduction
Fluoropyrimidine chemotherapy drugs such as 5-fluorouracil
(5FU) and the oral 5FU prodrugs are widely used as both
monotherapies and combination chemotherapy regime in the
treatment of a wide variety of cancers. Potential toxicities
associated with this class of chemotherapy include emesis,
diarrhea, mucositis, alopecia, myelosuppression, palmar-
plantar erythrodysesthesia, and cardiac toxicity. These
adverse reactions may be severe and rarely fatal. They often
compromise optimal patient treatment due to delays in drug
administration or discontinuation of therapy before comple-
tion of a planned treatment.
The DPYD gene encodes for the enzyme dihydropyrimidine
dehydrogenase (DPD), which functions as the rate-limiting
step in the metabolism of fluoropyrimidine chemotherapies1,2;
greater than 80% of 5FU is metabolized by DPD, and factors
such as age, race, comorbidities, and concomitant therapies
also influence metabolism (Figure 1). Over 50 polymorphisms
of DPYD have been described, with certain alleles associated
with reduced functionality of the enzyme leading to decreased
metabolism of 5FU and more treatment-based toxicities.3-8
Prospective testing for DPYD mutations is not routinely
carried out due to concerns over the cost-effectiveness of
upfront testing and the absence of clear guidelines for dose
reductions in patients found to be DPD deficient on prospective
testing.9 In addition, the absence of a mutation does not guar-
antee freedom from severe toxicity. Nonetheless, the potential
advantage of prospectively identifying DPYD mutations is
that careful monitoring and dose escalation may allow
DPD-deficient patients to safely receive fluoropyrimidine
chemotherapy.6-8
We became concerned by a number of patients treated at our
institution (a large Irish private hospital) suffering prolonged
hospitalizations, having to curtail or abandon adjuvant
chemotherapy due to fluoropyrimidine toxicity.10 In this study,
we followed current practice of reactive testing for DPYD
polymorphisms in patients experiencing severe toxicity. We
questioned whether prospective testing of all patients treated
during this period would reduce the economic and medical
toxicity of fluoropyrimidine-based treatment. We examined
the costs associated with an index admission for fluoropyri-
midine toxicity in DPD-deficient patients. A cost analysis was
undertaken comparing the anticipated cost and outcomes of
implementing screening for DPYD mutations as routine care
versus current practice.
Routine prospective screening can potentially benefit our
practice through the identification of those patients who are
at increased risk of toxicity. Subsequent individualization of
affected patients’ chemotherapy management may reduce the
risk of adverse outcomes.
Methods
Patient Population
Patients commencing chemotherapy for colorectal cancer
(CRC) at our institution over a 3-year period between January
1, 2010, and December 31, 2012, who developed severe (grade
3/4) toxicity were reactively tested for DPYD mutations. The
type and durations of toxicity were recorded using the National
Cancer Institute Common Toxicity Criteria for Adverse Events
version 4.0. Following informed consent, EDTA blood samples
were procured from each patient and genotyped for 4 DPYD
mutations associated with fluoropyrimidine toxicity at St Tho-
mas’ Hospital, London. The specific genotypes tested for were
1905þ1G>A (DPYD*2A), 2846A>T, 1601G>A (DPYD*4),
and 1679T>G (DPYD*13). From June 2011, quantitative poly-
merase chain reaction targeting 4 specific DPYD variants asso-
ciated with fluoropyrimidine toxicity was adopted as the testing
method. Prior to this, testing was performed by sequencing
exons 13, 14, and 22 (including 4 DPYD variants targeted by
the later method).
Economic Analysis
Cost analysis comparing the impact of systematic screening for
DPYD mutation with routine care was performed, consisting of
testing for DPYD mutation in the event of severe toxicity fol-
lowing commencement of chemotherapy. All costs are in form
of Euro (€) at 2012 values.
The cost of routine DPYD mutation testing if it had been
applied prospectively in all patients commencing on fluoropyr-
imidine therapy for CRC in this time frame was calculated.
Cost per test (€177) was obtained from internal hospital data
and then compared with the cost of the index admission with
grade 3/4 toxicity for the patients identified retrospectively as
having DPYD mutations. For patients with multiple admis-
sions, the cost of the key admission, which led to DPYD muta-
tion testing only, was assessed.
Figure 1. 5-Fluorouracil and capecitabine metabolism in liver and
tumor cells. CD indicates cytidine deaminase; CE, carboxyl esterase;
50-DFCR, 50-deoxy-5-fluorocytidine; 50-DFUR, 50-deoxy-5-
fluorouridine; DHFU, dihydro-5-fluorouracil; DPD, dihydropyrimidine
dehydrogenase; 5FU, fluorouracil; TP, thymidine phosphorylase.
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Costs associated with the study are based on microcosting
methods unless otherwise stated. The study was conducted in a
private hospital, enabling analysis of costs of care incurred by
individual patients. Discounting was not applied as only costs
associated with the index admission were evaluated. All costs
associated with treatment of severe toxicity at the index admis-
sion were analyzed. Mean patient costs for an admission for
severe toxicity are detailed in Table 1. Administrative and
overhead costs were excluded as they were considered to be
equivalent in both comparison groups. The primary analysis
was conducted from an Irish private hospital perspective.
Sensitivity Analysis
One-way sensitivity analysis was conducted on all known input
variables. Variations of +50% were applied due to the low
numbers involved in the study. An alternative scenario analy-
sis, from the perspective of the Irish health-care payer (respon-
sible for public hospitals) based on diagnosis-related group
costs, is also presented. Cost was based on an average length
of stay of 31.8 days for admission due to sequelae of treatment.
Budget impact analysis of potential costs and outcomes asso-
ciated with implementing DPYD screening at a national level
was also conducted. Analysis was informed by national inci-
dence, treatment, and mortality data.
Results
A total of 134 patients were commenced on first-line
fluoropyrimidine-based chemotherapy for CRC over the
3-year period, 66 in the adjuvant setting and 68 with metastatic
disease. In all, 30 patients (23%) developed grade 3/4 toxicity
during chemotherapy and therefore tested for DPYD mutations.
Of these, 5 (17% of those tested, 4.5% of total population)
revealed heterozygote DPYD mutations. Of the 4 deleterious
DPYD variants tested for, 2 were identified among our group of
patients with severe toxicity (DPYD*2A and *4). The DPYD
genotype, toxicity type, and duration of hospitalization are
summarized in Table 2.
The total cost related to hospitalization with toxicity for
these 5 patients was €232 061, an average of €46 412 per case.
At €177 per test, the cost to prospectively test all 134 patients
would have been €23 718. As seen in Table 3, if 60% of
patients identified with a DPYD mutation were prevented from
experiencing a severe toxicity resulting in hospitalization,
approximately €120 000 in additional cost would have been
avoided over a 3-year period.
Sensitivity Analysis
A wide variation was applied to help address uncertainty sur-
rounding the intervention. Variations of +50% were evaluated
during sensitivity analysis (Table 3). If only 30% of the patients
identified with DPYD mutations were successfully prevented
from experiencing severe toxicity, the proposed update in prac-
tice would still result in a cost saving. All scenarios evaluated
were in favor of routine DPD screening, including an analysis
from an Irish public hospital scenario.
Budget Impact Analysis
Based on a 2009 report, the average incidence of early-stage
(stage I-III) CRC in the Republic of Ireland is 1484 patients per
year11. Of these patients, 40% receive chemotherapy. Based on
estimates from the primary analysis presented in this article, the
budgetary impact of implementing DYPD screening on a rou-
tine basis is €105 000 per year; however, savings of approxi-
mately €630 000 could be achieved annually through the
prevention of unexpected hospital admissions for severe toxi-
city from fluoropyrimidine.
Discussion
The novel finding of our study is that cost of admissions for
severe chemotherapy-related toxicity with reactive DPYD test-
ing is higher than the cost of prospectively testing each new
patient commencing fluoropyrimidine chemotherapy.
Using a panel of 4 mutations associated with fluoropyrimi-
dine toxicity, we report a prevalence of heterozygous DPYD
mutation in this Irish population with CRC of 4.5%. DPYD
mutations were found to be present in a sizeable minority
(17%) of patients developing grade 3/4 toxicities with fluoro-
pyrimidine therapy. Previous studies have described deleter-
ious mutations in DPYD in up to 12% to 25% of patients
developing grade 3/4 toxicities with fluoropyrimidine-based
chemotherapy,12-15 although curiously one study found the
dominant *2A polymorphism in as low as 2.2% of patients with
severe toxicity.16
To date, there have been some proponents of routine testing
for DPD deficiency prior to starting treatment17; however,
these remain the minority, the perceived wisdom being that
preemptive screening is not cost-effective. This consensus was
challenged by a nonrandomized study in patients receiving
fluoropyrimidine-based chemotherapy for CRC, demonstrating
that prospective screening for DPD deficiency (genotype +
phenotype) could be a cost-effective strategy.18 Our study sup-
ports this finding by showing that routine prospective DPYD
Table 1. Mean Patient Costs for Index Admission With Severe
Toxicity.
Category Mean (€) Standard Deviation
Accommodation fees 25 981 14 893
Consumables 114 242
Paramedical 4063 4229
Pathology 12 017 11 570




Theater/ward packs 244 141
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mutation testing in the Irish population would be associated
with significant cost savings.
Patients reactively diagnosed with DPYD mutations follow-
ing admissions with severe toxicity were unlikely to resume
therapy at reduced doses, potentially compromising curative
outcomes.19 Prospective identification of patients with a DPYD
mutation, coupled with dose reduction from therapy initiation,
may protect patients, improve quality of life, and avoid severe
and potentially fatal chemotherapy-related toxicity.
Although the practice of pharmacogenomic drug dosing is in
its infancy, the Clinical Pharmacogenetics Implementation
Consortium (CPIC) has published guidelines containing dosing
recommendations for fluoropyrimidines based on DPYD gen-
otype.20 They recommend a minimum of a 50% reduction in
the initiation dose in patients heterozygous for the nonfunc-
tional alleles *2a, *13, and 2846A>T. Notably, the consortium
currently recommend that the *4 variant be categorized as
“normal” activity, in part based on functional analyses of enzy-
matic activity in transfected cell lines which suggested supra-
normal activity.21,22 This is, however, contradictory to our
study: the *4 allele was identified as a heterozygote variant
in 2 of our patients with severe toxicity and a compound
heterozygote in combination with the *2A variant in another.
This variant has been found to be previously associated with
decreased enzyme activity in functional analyses of human
donor peripheral blood mononuclear cells, as well as severe
toxicity in patients receiving fluoropyrimidines.6,23-25 We sug-
gest that initial dose reduction for this variant should continue
to be considered, while we recognize that further study is
required to produce more definitive pharmacogenomic-based
dosing guidelines.
By definition, pharmacogenomic dosing will vary between
individuals, with initial dose reduction needing adjustment on a
patient-by-patient basis. Currently, the CPIC guidelines do not
report dosing recommendations for all variants of DPYD, due
to weak or conflicting data on the effect these alleles have on
DPD activity.
There is understandable concern that patients may have dose
reductions performed for identified mutations which may not
have resulted in increased toxicity, resulting in patients receiv-
ing reduced doses of potentially curative chemotherapy with-
out achieving a gain from toxicity avoidance. Additional
information regarding the increased toxicity associated with
various polymorphisms is required to optimize pharmacoge-
nomic dosing. Currently, it is reasonable to reduce doses appro-
priately for the better characterized polymorphisms listed
above and avoid testing for polymorphisms of as yet undeter-
mined significance. Similarly, where such polymorphisms are
detected, one may recommend increased education and vigi-
lance for toxicity in such patients, without utilizing dose reduc-
tions from the start of therapy.
One way to clearly establish predictable drug exposure to
minimize undue toxicity while maximizing therapeutic expo-
sure is to conduct continuous pharmacokinetic monitoring,
as has been utilized in a French study.26-28 Although this is
an interesting concept, it is an excessively labor-intensive
and time-consuming approach rendering it impractical in
clinical practice.
Our study suggests that while routine testing is economi-
cally viable, further research and clear guidance on dose reduc-
tion are needed. DPYD testing has the potential to avoid
premature cessation of potentially curative therapy for patients
with deficiencies.
We acknowledge that this was a small single-center-based
study and that results may be biased by the fact that 2 of the
hospitalized cases required prolonged treatment in an intensive
Table 2. Characteristics of Patients Diagnosed With DPYD Mutations.
Pt Gender Regimen Cycle of Toxicity Type of Toxicity Mutation Status Length of Admission (Days)
1 Female FLOX Post C1D15 GI *4 Heterozygous 64
2 Male mFolfox6 Post C4 GI and hematologic *2A Heterozygous 37
3 Female Xelox Post C2* GI Compound *2A & *4 Heterozygous 26
4 Male mFolfox6 Post C4 GI *4 Heterozygous 17
5 Male mFolfox6 Post C1 GI and hematologic *2A Heterozygous 15
Abbreviations: C, cycle; D, day; GI, gastrointestinal; Pt, patient.
aPatient 3 had received previous capecitabine therapy with neoadjuvant radiation, requiring dose reductions for toxicity.
Table 3. Costs of Systematic Screening Versus Usual Care of 134
Patients Commenced on First-Line Fluoropyrimidine-Based





Cost of DPYD screening 23 718 5310
Cost of severe toxicity-related admission
to hospital
92 824a 232 061
Total cost of care 116 542 232 371
Incremental cost of systematic screening
versus usual care
120 829
Effectiveness of DPYD screening and
altered chemotherapy protocols (lower
limit ¼ 30% success; upper limit ¼ 90%
success)
51 210 190 447
Cost of hospital care (+95% confidence
interval)
37 265 204 392
Irish health-care payer scenario 54 074
aBased on the assumption that routine screening for DPYD mutations and
revised chemotherapy protocol has a 60% success rate in preventing severe
toxicity-related admissions.
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care unit. Nonetheless, proposed routine screening of patients
remained cost beneficial in all sensitivity analysis conducted,
including one encompassing an approximate 50% reduction in
costs. As with the vast majority of clinical-based studies, the
diverse nature of health-care systems across jurisdictions must
be considered when analyzing results; however, it must be
noted that the costs of inpatient care for complications due to
both medical and surgical therapy were among the fastest rising
costs of hospital stays in US health care in 2010.29
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